Every peptide, mapped to the body.

153 peptides, from approved drugs to compounds still in trials, sorted by where they act.

FDA-approved
In clinical trials
Wellness and performance
Cosmetic and topical

Loading the body

In clinical trials

Hormones & metabolism

Efpeglenatide

EvidenceDeep research

ClassLong-acting GLP-1 agonist

Efpeglenatide is an investigational once-weekly GLP-1 receptor agonist. Learn how it works, what the AMPLITUDE-O trial found, and why it is not yet approved.

Reviewed by: William Maish, MD MBA MPH, Clinical Product Lead
Published: October 5, 2026
Last updated: October 5, 2026

Key takeaway

Efpeglenatide is an investigational long-acting GLP-1 receptor agonist, originally developed by Hanmi Pharmaceutical, given as a once-weekly injection for type 2 diabetes and cardiovascular risk. In a large Phase 3 outcomes trial it reduced major cardiovascular events in people with type 2 diabetes. As of 2026, it has not reached approval in major markets.

At a glance

FDA status	Investigational peptide, not approved by the FDA or EMA
What it is	Long-acting GLP-1 receptor agonist given as a once-weekly injection
Research	A large Phase 3 cardiovascular outcomes trial (AMPLITUDE-O) reported positive results
Development	Rights returned to Hanmi, which has pursued regional licensing
Evidence strength	Deep research

What is efpeglenatide?

Efpeglenatide is an experimental GLP-1 receptor agonist built on an exendin-based peptide with a half-life-extension technology that allows once-weekly injection. It was developed by Hanmi Pharmaceutical and was previously licensed to Sanofi, which later returned the rights. It has been studied for type 2 diabetes and cardiovascular and kidney risk, and it is investigational, not approved in major markets.

How does it work?

Efpeglenatide activates the GLP-1 receptor¹, the same incretin target as drugs such as semaglutide and dulaglutide. Activation of the receptor:

Enhances glucose-dependent insulin secretion
Suppresses glucagon
Slows gastric emptying
Reduces appetite

In people with type 2 diabetes these effects lower blood sugar and body weight, and GLP-1 agonists as a class have also shown cardiovascular benefits. This describes the mechanism, separate from the trial outcomes below.

Is it FDA-approved?

No. Efpeglenatide is investigational and not approved by the FDA or EMA. After Sanofi returned development rights, Hanmi took the program back in-house and has pursued regional licensing arrangements, but no major-market approval exists.

What does the research show?

The key evidence is a large cardiovascular outcomes trial. According to PubMed, the Phase 3 AMPLITUDE-O² trial enrolled over 4,000 adults with type 2 diabetes who had cardiovascular or kidney disease. The table summarizes what it and a follow-up analysis reported:

Endpoint	Finding
Major adverse cardiovascular events	Occurred less often with efpeglenatide than placebo (hazard ratio 0.73)
Composite kidney outcome	Reduced with efpeglenatide
Benefit by SGLT2 inhibitor use	A prespecified analysis³ found the benefit was consistent regardless of whether participants were already taking an SGLT2 inhibitor

These are positive, peer-reviewed Phase 3 results, although the program has not reached approval.

More for hormones & metabolism

Sources: the AMPLITUDE-O trial (Gerstein et al., New England Journal of Medicine, 2021, DOI: 10.1056/NEJMoa2108269²) and a prespecified subgroup analysis (Lam et al., Circulation, 2021, DOI: 10.1161/CIRCULATIONAHA.121.057934³), both indexed on PubMed. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.